Cargando…
BRAF mutation correlates with worse local–regional control following radiation therapy in patients with stage III melanoma
BACKGROUND: In patients with stage III melanoma, the use of adjuvant radiation therapy (RT) after lymph node dissection (LND) may be currently considered in selected high-risk patients to improve tumor control. Melanomas harbor BRAF mutations (BRAF+) in 40–50% of cases, the majority of which are on...
Autores principales: | Wolfe, Adam R., Chablani, Priyanka, Siedow, Michael R., Miller, Eric D., Walston, Steve, Kendra, Kari L., Wuthrick, Evan, Williams, Terence M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449455/ https://www.ncbi.nlm.nih.gov/pubmed/34537078 http://dx.doi.org/10.1186/s13014-021-01903-5 |
Ejemplares similares
-
Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma
por: Faut, Marloes, et al.
Publicado: (2018) -
Multidisciplinary Care of BRAF‐Mutant Stage III Melanoma: A Physicians Perspective Review
por: Cornelius, Lynn A., et al.
Publicado: (2021) -
Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
por: Homan, Morgan, et al.
Publicado: (2022) -
Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011) -
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
por: Vidarsdottir, Linda, et al.
Publicado: (2021)